Patent ID: 9746479
Date: 2017-08-29
CPC Classifications: C12Q,G01N

Claim:
1. A method comprising: obtaining a urinary cell sample from a human patient with a renal allograft but without acute cellular rejection of the allograft; quantifying mRNA expression levels of perforin, granzyme B, PI-9, IP-10, CD3, FoxP3, and CXCR3 in the urinary cell sample of the patient; comparing the quantified mRNA expression levels in the urinary cell sample to a corresponding baseline level of mRNA expression of perforin, granzyme B, PI-9, IP-10, CD3, FoxP3, and CXCR3 in urinary cells from a healthy subject or a subject with a non-rejecting renal allograft; detecting upregulation of mRNA expression of perforin, granzyme B, PI-9, IP-10, CD3, and CXCR3 in the urinary cell sample of the patient and initiating treatment with, or providing a modified dose of, an anti-rejection agent to the patient, or detecting upregulation of mRNA expression of perforin, IP-10, FoxP3, and CXCR3 in the urinary cell sample of the patient and initiating treatment with, or providing a modified dose of, an anti-rejection agent to the patient; and obtaining an additional urinary cell sample from the patient after said initiating treatment with, or providing a modified dose of, an anti-rejection agent, and quantifying mRNA expression levels of perforin, granzyme B, PI-9, IP-10, CD3, FoxP3, and CXCR3 in the additional urinary cell sample from the patient.